John R. Stuelpnagel, Director at 10x Genomics, Inc. (TXG), sold 7,100 shares at $182.74 ($1.3M) on 2021-08-02, disclosed to the SEC on 2021-08-04.
Open-market sale of $1.3M TXG by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $178.48 | 1,100 | $196K | 15.3% |
| 2 | $179.53 | 1,140 | $205K | 16.0% |
| 3 | $179.53 | 1,140 | $205K | 16.0% |
| 4 | $180.33 | 960 | $173K | 13.5% |
| 5 | $180.33 | 960 | $173K | 13.5% |
| 6 | $181.47 | 1,100 |
| $200K |
| 15.6% |
| 7 | $182.74 | 400 | $73K | 5.7% |
| 8 | $183.90 | 200 | $37K | 2.9% |
| 9 | $184.99 | 100 | $18K | 1.4% |
| Total | $180.27 avg | 7,100 | $1.3M | 100% |
| Filing → |
| TXG | SELL | 2023-06-07 | $549K | — | Filing → |
| TXG | SELL | 2022-01-04 | $1.5M | — | Filing → |
| TXG | SELL | 2021-12-03 | $756K | — | Filing → |